A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibitionDaniel S. Lenchner, Frederick H. Wilson|npj Precision Oncology|2024Cited by 4
Genetic and oncogenic features of RASGRF fusionsSreya Das, Frederick H. Wilson|npj Precision Oncology|2025Cited by 2